Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality®▼ (galcenezumab) device: Disposal
The pen or syringe should be disposed in a sharps disposal container.
After the medicine has been injected, the base cap of the pen or the needle cap of the syringe should not be placed back onto the device. They can be thrown away in the bin.1
The pen or syringe should be disposed in a sharps disposal container. Patients should follow the instructions of their doctor, pharmacist or nurse for device disposal.1
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.3
3. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: February 15, 2019